Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 7/7/2020
SIETES contiene 93061 citas

 
 
 1 a 13 de 13 
Presentar resultados
Seleccionar todas
1. Cita con resumen
White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L, for the CARES Investigators. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 2018;378:29 de marzo. [Ref.ID 102489]
2. Cita con resumen
Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorenzton M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 2017:11 de septiembre. [Ref.ID 102052]
3. Cita con resumen
Yun H, Xie F, Delzell E, Levitan EB, Chen L, Lewis JD, Saag KG, Beukelman T, Winthrop KL, Baddley JW, Curtis JR. Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in Medicare. Arthritis Rheum 2016;68:56-66. [Ref.ID 99975]
4. Cita con resumen
Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, Beukelman T, Patkar NM, Xie F, Saag KG, Herrinton LJ, Solomon DH, Lewis JD, Curtis JR. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013;309:887-95. [Ref.ID 95064]
5. Cita con resumen
Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, Saag KG, Baddley JW, Curtis JR. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012;308:43-9. [Ref.ID 93391]
6.Tiene citas relacionadas Cita con resumen
Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, Griffin MR, Herrinton LJ, Liu L, Ouellet-Hellstrom R, Patkar NM, Solomon DH, Lewis JD, Xie F, Saag KG, Curtis JR. Initiation of tumor necrosis factor-a antagonists and the risk of hospitalization for infections in patients with autoimmune diseases. JAMA 2011;306:2331-9. [Ref.ID 91921]
7.Tiene citas relacionadas Cita con resumen
Grijalva CG, Chen L, Baddley JW, Beukelman T, Winthrop KL, Griffin MR, Herrinton LJ, Ouellet-Hellstrom R, Patkar NM, Solomon DH, Lewis JD, Xie F, Saag KG, Curtis JR. Initiation of tumor necrosis factor-alfa antagonists and the risk of hospitalization for infection in patients with autoimmune diseses. JAMA 2011;306:2331-9. [Ref.ID 91686]
8.Tiene citas relacionadas
Saag KG, Shane E, Marcus R. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. The authors reply. N Engl J Med 2008;358:1303-4. [Ref.ID 82474]
9.Tiene citas relacionadas Cita con resumen
Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007;357:2028-39. [Ref.ID 81509]
10.Tiene citas relacionadas
Allison JJ, Saag KG. Unbalanced regulation of over-the-counter analgesics: the lesser of two evils?. Pharmacoepidemiol Drug Saf 2006;15:410-1. [Ref.ID 77537]
11.
Shatin D, Rawson NSB, Curtis JR, Braun MM, Martin CK, Moreland LW, Becker AF, Patkar NM, Allison JJ, Saag KG. Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventions15. Pharmacoepidemiol Drug Saf 2006;15:11-8. [Ref.ID 76035]
13. Cita con resumen
Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG, for The Glucocorticoid-Induced Osteoporosis Intervention Study Group. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339:292-9. [Ref.ID 39370]
Seleccionar todas
 
 1 a 13 de 13